How do you treat patients with advanced NSCLC in the era of immunotherapy? In this commentary, Dr. Gubens discusses the latest data on frontline combination regimens using immunotherapy for the treatment of advanced NSCLC.
How do you manage patients with advanced squamous NSCLC in the era of immunotherapy? In this commentary, H. Jack West, MD, discusses the latest treatment options for advanced squamous NSCLC involving immune checkpoint inhibitors.
To benefit from targeted therapies for patients with advanced NSCLC, it is imperative that clinicians use biomarker testing to identify potential actionable gene aberrations. In this commentary, Joel Neal, MD, PhD, discusses his approach to this dynamic aspect of clinical care.
The combination of nivolumab and ipilimumab, with or without chemotherapy, is now approved for advanced NSCLC. Read my thoughts on the rationale for these approvals and how to integrate these regimens into clinical practice.